-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Bnm35E5p7SHv9GYY093FCs9nh6lPFnLduX3gY57HlDEW4Yl/3A9ePEZHdaBwQMrZ
 DpAFzZPC1MxKUtsrhhbDRQ==

<SEC-DOCUMENT>0001181431-10-011087.txt : 20100223
<SEC-HEADER>0001181431-10-011087.hdr.sgml : 20100223
<ACCEPTANCE-DATETIME>20100223102937
ACCESSION NUMBER:		0001181431-10-011087
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20100223
FILED AS OF DATE:		20100223
DATE AS OF CHANGE:		20100223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			3SBio Inc.
		CENTRAL INDEX KEY:			0001383790
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33295
		FILM NUMBER:		10624622

	BUSINESS ADDRESS:	
		STREET 1:		NO.3 A1, ROAD 10 SHENYANG
		STREET 2:		ECONOMY & TECHNOLOGY DEVELOPMENT ZONE
		CITY:			SHENYANG
		STATE:			F4
		ZIP:			110027
		BUSINESS PHONE:		86-24-2581-1820

	MAIL ADDRESS:	
		STREET 1:		NO.3 A1, ROAD 10 SHENYANG
		STREET 2:		ECONOMY & TECHNOLOGY DEVELOPMENT ZONE
		CITY:			SHENYANG
		STATE:			F4
		ZIP:			110027
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>rrd267076.htm
<TEXT>

<html>
<head>
<title>Prepared By R.R. Donnelley - Form 6-K</title>
</head>
<body bgcolor="WHITE">


<hr align="left" color="#000000" noshade="noshade" size="3">

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="5"><b>SECURITIES AND EXCHANGE COMMISSION</b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="3"><b>Washington, DC 20549 </b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<hr color="#000000" noshade="noshade" size="1" width="17%">

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="5"><b>FORM 6-K</b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"></font>
</p>

<hr color="#000000" noshade="noshade" size="1" width="17%">

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="3"><b>REPORT OF FOREIGN PRIVATE ISSUER </b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="3"><b>Pursuant to Rule 13a-16 or 15d-16 of</b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="3"><b>the Securities Exchange Act of 1934 </b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2"><b>February 23, 2010</b></font>
</p>

	<p style="margin-top: 0px; margin-bottom: 0px;">
		<font size="1"> </font>
	</p>



	<hr color="#000000" noshade="noshade" size="1" width="17%">

	<p style="margin-top: 0px; margin-bottom: 0px;">
		<font size="1"> </font>
	</p>

	<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
		<font face="Times New Roman" size="6"><b>3SBio Inc.</b></font>
	</p>

	<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
		<font face="Times New Roman" size="1"><b>(Translation of registrant's name into English) </b></font>
	</p>

	<p style="margin-top: 0px; margin-bottom: 0px;">
		<font size="1"> </font>
	</p>

	<hr color="#000000" noshade="noshade" size="1" width="17%">

	<p style="margin-top: 0px; margin-bottom: 0px;">
		<font size="1"> </font>
	</p>
	<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
		<font face="Times New Roman" size="2">
			<b>
				No. 3 A1, Road 10<br>Shenyang Economy & Technology Development Zone<br>Shenyang 110027<br>People's Republic of China
			</b>
		</font>
	</p>

	<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
		<font face="Times New Roman" size="1"><b>(Address of principal executive offices) 	</b></font>
	</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<hr color="#000000" noshade="noshade" size="1" width="90%">

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">Indicate by check mark whether the registrant files or will </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">file annual reports under
cover of Form 20-F or Form 40-F. </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">
		Form 20-F <u><b>&nbsp;&nbsp;X&nbsp;&nbsp;</b></u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
	</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font face="Times New Roman" size="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
		<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
	</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font face="Times New Roman" size="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):
		<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
	</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">Indicate by check mark whether the registrant by furnishing the </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">information contained
in this form is also thereby furnishing the </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">information to the Commission pursuant to Rule 12g3-2(b) under the </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">Securities Exchange Act of 1934.</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">
		Yes
		<u>&nbsp;&nbsp;&nbsp;</u>
		&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		No
		<u><b>&nbsp;&nbsp;X&nbsp;&nbsp;</b></u>
	</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">If "Yes" is marked, indicate below the file number assigned to the </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">registrant in connection with Rule 12g3-2(b): <u>82-</u>.
</font>
</p>

<p style="margin-top: 0px; margin-bottom: -6px;">
	<font size="1"> </font>
</p>

<hr align="left" color="#000000" noshade="noshade" size="3">

<hr align="center" color="#999999" size="3" width="100%">

<p style="margin-top: 0px; margin-bottom: -6px;">
 	<font face="Times New Roman" size="2">
 		3SBio Inc. is furnishing under the cover of Form 6-K:<p>Exhibit 99.1 Press release, dated February 11, 2010, regarding that 3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics &nbsp;
	</font>
</p>

<hr align="center" color="#999999" size="3" width="100%">

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">SIGNATURES </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px; text-indent: 4%;">
	<font face="Times New Roman" size="2">Pursuant
	to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by
	the
	undersigned, thereunto duly authorized. </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">

			<tr>
				<td valign="top">
					<p style="margin-left: 1em; text-indent: -1em;">
						<font face="Times New Roman" size="2">

						</font>
					</p>
				</td>
				<td colspan="3" valign="top">

						<font face="Times New Roman" size="2">
							3SBio Inc.
						</font>

				</td>
			</tr>

			<tr>
				<td valign="top">

						<font face="Times New Roman" size="2">
							Date : February 23, 2010
						</font>

				</td>
				<td valign="top">

						<font face="Times New Roman" size="2">
							By:
						</font>

				</td>

				<td valign="bottom">
					<font size="1"> </font>
				</td>
				<td valign="bottom">

						<font face="Times New Roman" size="2">
							<u>/s/ Dr. Jing Lou&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
						</font>


				</td>
			</tr>
			<tr>
				<td valign="top">

						<font face="Times New Roman" size="2">

						</font>

				</td>
				<td valign="top">

						<font face="Times New Roman" size="2">
							Name:
						</font>

				</td>
				<td valign="bottom">
					<font size="1"> </font>
				</td>
				<td valign="bottom">

						<font face="Times New Roman" size="2">
							Dr. Jing Lou
						</font>

				</td>
			</tr>
			<tr>
				<td valign="top">

						<font face="Times New Roman" size="2">
							&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
						</font>

				</td>
				<td valign="top">

						<font face="Times New Roman" size="2">
							Title:
						</font>

				</td>

				<td valign="bottom">
					<font size="1"> </font>
				</td>
				<td valign="bottom">

						<font face="Times New Roman" size="2">
							Chief Executive Officer
						</font>

				</td>
			</tr>
			<tr>
				<td>
					&nbsp;
				</td>
			</tr>


		</table>


	<p Style='page-break-before:always'>
	<hr  Size="3" Width="100%" Align="center">
		<div Align="center"><font Face="times New Roman" Size="3" Color="#000000">
	<b>Exhibit Index </b></font>
	</div>

	<div><font Size="2">&nbsp;</font></div>

	<div Align="center">
	<table Cellspacing="0" Cellpadding="0" Width="100%" Border="0">
		<tr>
			<td Valign="top" Align="left">
		<div Align="left"><font Face="times New Roman" Size="2" Color="#000000">
		<b>Exhibit&nbsp;No.</b></font>
		</div>
			<hr Size="2" Noshade Width="48" Color="#000000">
			</td>
			<td Valign="top" Width="3%"><font Face="times New Roman" Size="2">&nbsp;&nbsp;</font></td>
			<td Valign="top" Width="100%" Align="left">
		<div><font Face="times New Roman" Size="2" Color="#000000">
		<b>Description</b></font>
		</div>
		<hr Size="2" Noshade Width="73" Align="left" Color="#000000">
			</td>
		</tr>


		<tr>
			<td Valign="top" Align="left">
		<div Align="left"><font Face="times New Roman" Size="1" Color="#000000">
		EX-99.1</font>
		</div>

			</td>
			<td Valign="top" Width="3%"><font Face="times New Roman" Size="2">&nbsp;&nbsp;</font></td>
			<td Valign="top" Width="100%" Align="left">
		<div><font Face="times New Roman" Size="2" Color="#000000">
		3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics</font>
		</div>
			</td>
		</tr>
		<tr>
			<td>
				&nbsp;
			</td>
		</tr>


		</table>


<BR><BR><BR>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rrd267076_318.htm
<DESCRIPTION>3SBIO AND ASCENTAGE PHARMA FORM STRATEGIC ALLIANCE TO RESEARCH, DEVELOP AND COMMERCIALIZE CANCER THERAPEUTICS
<TEXT>
<HTML>
<HEAD>
<TITLE>FOR RELEASE NOVEMBER 12, 2009 5:00 pm Eastern Time</TITLE>
<META NAME="DocID_Include" CONTENT="On">
</HEAD>
<BODY>
<B><P ALIGN="JUSTIFY"></P>
</B><P ALIGN="JUSTIFY">FOR RELEASE FEBRUARY 11, 2010 8:00 pm Eastern Time</P>
<B><FONT SIZE=2><P ALIGN="JUSTIFY"></P>
</B></FONT><FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;</P><DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
</FONT><B><P ALIGN="CENTER">3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics</P>
<FONT SIZE=2><P>&nbsp;</P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
<P ALIGN="JUSTIFY">SHENYANG, CHINA</B> - February 11, 2010 - 3SBio Inc. (NASDAQ: SSRX) (&quot;3SBio&quot; or &quot;the Company&quot;), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. (&quot;Ascentage Pharma&quot;) announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China. </P>
<P ALIGN="JUSTIFY">Under the terms of the agreement, 3SBio will make a US$3 million equity investment in Ascentage Pharma. The investment will be used to fund Ascentage Pharma's R&amp;D programs.  3SBio will have the exclusive right to develop and commercialize cancer therapeutics in China that are discovered through Ascentage Pharma programs, while Ascentage Pharma will retain the rights to the rest of the world and receive future milestone and royalty payments from any sales by 3SBio in China. &nbsp;</P>
<P ALIGN="JUSTIFY">"The collaboration with Ascentage Pharma represents a key strategic initiative for 3SBio to develop our pipeline in the area of cancer therapeutics," said Dr. Jing Lou, CEO of 3SBio.   &quot;This investment allows 3SBio to gain access to the best external science and small molecule drug discovery platform in China." </P>
<P ALIGN="JUSTIFY">"Apoptosis targeted small molecule has the potential to play a key role in the next generation of highly effective targeted cancer drugs," said Dr. Dajun Yang, CEO of Ascentage Pharma.  &quot;We believe that this &quot;win-win&quot; collaboration will generate innovative medicines that benefits patients worldwide.&quot; </P>
<B><P>About 3SBio Inc. <BR>
</B>3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at </FONT><FONT FACE="Lucida Sans" SIZE=2><FONT FACE="Lucida Sans" SIZE=2>www.3sbio.com </P>
</FONT></FONT><B><FONT SIZE=2><P ALIGN="JUSTIFY">About Ascentage Pharma Group Corporation, Ltd. </P>
</B><P ALIGN="JUSTIFY">Ascentage Pharma is a recent spin-off of Ascenta (Shanghai) R&amp;D Center, a wholly owned subsidiary of Ascenta Therapeutics, Inc. which was established in August 2005. The new company, including the team and facility, became independent in the summer 2009. The team has an established track record in late stage discovery, preclinical and IND enabling work, working with both China's SFDA and the US FDA.&nbsp; Ascentage Pharma will focus on oncology new chemical entity (NCE) drug R&amp;D using cutting edge apoptosis technology, building on molecules and compounds licensed from the University of Michigan. The company aims to develop best-in-class targeted therapeutics for the unmet medical needs of both China and global markets.</P>
<P>&nbsp;</P>
<B><P ALIGN="JUSTIFY">Safe Harbor Statement </P>
</B><I><P ALIGN="JUSTIFY">This press release contains statements of a forward-looking nature. These statements are made under the &quot;safe harbor&quot; provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as &quot;will,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;future,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates&quot; and similar statements. The accuracy of these statements may be impacted by a number of business factors and uncertainties that could cause actual results to differ materially from those projected or anticipated, including factors related to: the risk that Ascentage Pharma's R&amp;D programs will not result in therapeutics which produce satisfactory results in clinical trials or obtain SFDA approval due to the inherent uncertainty of the timing and success of pharmaceutical research and development projects or that Ascentage will require additional 
funding to develop new therapeutics; the risk that 3SBio may not be successful in commercializing any therapeutics developed by Ascentage Pharma pursuant to their strategic alliance due to difficulties or delays in manufacturing, lack of demand by hospitals and doctors or other factors; the risk of intellectual property disputes arising with third parties in connection with newly developed therapeutics; the risk that the strategic alliance will not continue for its full term for whatever reason; uncertainties regarding 3SBio's ability to obtain favorable insurance coverage and pricing for any therapeutics developed by Ascentage Pharma; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the P.R.C. government and changes in the healthcare insurance sector in the P.R.C.; fluctuations in general economic and business conditions in China; and other risks outlined in 3SBio's filings with the Securities and Exchange Commission. 3SBio does not undertake any o
bligation to update this forward-looking information, except as required under applicable law. </P>
</I><B><P>Investor Contacts</P>
</B><P>Bo Tan<BR>
Chief Financial Officer<BR>
3SBio Inc.<BR>
Tel: + 86 24 2581-1820<BR>
</FONT><FONT FACE="Lucida Sans" SIZE=2><FONT FACE="Lucida Sans" SIZE=2>ir@3SBio.com</P>
</FONT></FONT><FONT SIZE=2><P>Tom Folinsbee<BR>
Director of Investor Relations<BR>
3SBio Inc. <BR>
Tel: + 852 8191-6991<BR>
</FONT><FONT FACE="Lucida Sans" SIZE=2><FONT FACE="Lucida Sans" SIZE=2>ir@3SBio.com</P>
</FONT></FONT><FONT SIZE=2><P>&lt;END&gt;</P>
</FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
